Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VDR | P11473 | 12/20 | 0.75 |
| ▸ | MAPT | P10636 | 3/20 | 0.75 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.75 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.75 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.75 |
| ▸ | GC | P02774 | 1/20 | 0.75 |
| ▸ | PGR | P06401 | 1/20 | 0.75 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.75 |
| ▸ | RXRA | P19793 | 1/20 | 0.75 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.75 |
| ▸ | CNR1 | P21554 | 1/20 | 0.75 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.75 |
| ▸ | HTR2C | P28335 | 1/20 | 0.75 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.75 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.75 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.75 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.75 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.75 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.75 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11317373 | 1.00 | VDR (0.75) | VDRMAPTSMN1; SMN2NR1I2ABCB11 | |
| SCHEMBL5305802 | 1.00 | VDR (0.75) | VDRMAPTSMN1; SMN2NR1I2ABCB11 | |
| SCHEMBL11226670 | 1.00 | VDR (0.75) | VDRMAPTSMN1; SMN2NR1I2ABCB11 | |
| SCHEMBL23359104 | 0.92 | VDR (0.77) | VDRMAPTSMN1; SMN2NR1I2ABCB11 | |
| SCHEMBL9001015 | 0.92 | VDR (0.77) | VDRMAPTSMN1; SMN2NR1I2ABCB11 | |
| SCHEMBL23359105 | 0.92 | VDR (0.77) | VDRMAPTSMN1; SMN2NR1I2ABCB11 | |
| SCHEMBL5872989 | 0.91 | VDR (0.76) | VDRMAPTSMN1; SMN2NR1I2ABCB11 | |
| SCHEMBL6402298 | 0.91 | VDR (0.76) | VDRMAPTSMN1; SMN2NR1I2ABCB11 | |
| SCHEMBL5873196 | 0.91 | VDR (0.76) | VDRMAPTSMN1; SMN2NR1I2ABCB11 | |
| SCHEMBL6401347 | 0.91 | VDR (0.76) | VDRMAPTSMN1; SMN2NR1I2ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0401357-B1 | IMPROVING REPRODUCTIVE FUNCTIONS IN MAMMALS | WISCONSIN ALUMNI RES FOUND (US) | 1996-03-20 | — | — | EP | claimed |
| EP-0401357-A1 | METHOD FOR IMPROVING REPRODUCTIVE FUNCTIONS IN MAMMALS. | WISCONSIN ALUMNI RES FOUND (US) | 1990-12-12 | — | — | EP | claimed |
| WO-1990006121-A2 | METHOD FOR IMPROVING REPRODUCTIVE FUNCTIONS IN MAMMALS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1990-06-14 | — | — | WO | claimed |
| EP-2190422-A1 | A METHOD OF EXTENDING THE DOSE RANGE OF VITAMIN D COMPOUNDS | Wisconsin Alumni Research Foundation (US) | 2010-06-02 | — | — | EP | disclosed |
| WO-2009026265-A1 | A METHOD OF EXTENDING THE DOSE RANGE OF VITAMIN D COMPOUNDS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2009-02-26 | — | — | WO | disclosed |
| US-20080249068-A1 | Method of Extending the Dose Range of Vitamin D Compounds | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2008-10-09 | — | — | US | disclosed |
| US-7259143-B2 | Method of extending the dose range of vitamin D compounds | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2007-08-21 | — | — | US | disclosed |
| EP-1545549-A1 | A METHOD OF EXTENDING THE DOSE RANGE OF VITAMIN D COMPOUNDS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2005-06-29 | — | — | EP | disclosed |
| US-20040053813-A1 | Method of extending the dose range of vitamin D compounds | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2004-03-18 | — | — | US | disclosed |
| WO-2004022068-A1 | A METHOD OF EXTENDING THE DOSE RANGE OF VITAMIN D COMPOUNDS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2004-03-18 | — | — | WO | disclosed |
| US-20020045772-A1 | Vitamin D derivative having substituent at 2beta-position | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2002-04-18 | — | — | US | disclosed |
| US-6291444-B1 | Treatment of t-cell immunodeficiencies with vitamin D compounds | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2001-09-18 | — | — | US | disclosed |
| EP-1070704-A1 | VITAMIN D DERIVATIVES SUBSTITUTED AT THE 2$g(b)-POSITION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2001-01-24 | — | — | EP | disclosed |
| EP-0401357-B1 | IMPROVING REPRODUCTIVE FUNCTIONS IN MAMMALS | WISCONSIN ALUMNI RES FOUND (US) | 1996-03-20 | — | — | EP | disclosed |
| EP-0549367-A1 | Method of treating milk fever disease in dairy cattle | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1993-06-30 | — | — | EP | disclosed |
| EP-0401357-A1 | METHOD FOR IMPROVING REPRODUCTIVE FUNCTIONS IN MAMMALS. | WISCONSIN ALUMNI RES FOUND (US) | 1990-12-12 | — | — | EP | disclosed |
| WO-1982002893-A1 | 1 ALPHA,25-DIHYDROXY-2 BETA-FLUOROVITAMIN D3 | WISCONSIN ALUMNI RES FOUND (US) | 1982-09-02 | — | — | WO | disclosed |
| US-4307025-A | 1α, 25-dihydroxy-2β-fluorovitamin D3 | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1981-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020045772-A1 | Vitamin D derivative having substituent at 2beta-position | CYP2R1, CYP24A1, VDR | VDR 3/4885MAPT 4885/4885SMN1; SMN2 4862/4885 |
| US-20080249068-A1 | Method of Extending the Dose Range of Vitamin D Compounds | VDR, CASK, CYP24A1 | VDR 1/4885MAPT 3703/4885SMN1; SMN2 3869/4885 |
| US-20040053813-A1 | Method of extending the dose range of vitamin D compounds | VDR, SOST, CASK | VDR 1/4885MAPT 3886/4885SMN1; SMN2 3375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.